Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ocuphire Pharma, Inc. (OCUP)

3.65   -0.14 (-3.69%) 03-22 15:29
Open: 3.76 Pre. Close: 3.79
High: 3.765 Low: 3.625
Volume: 13,763 Market Cap: 76(M)

Technical analysis

as of: 2023-03-22 3:20:15 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 4.54     One year: 5.3
Support: Support1: 3.53    Support2: 3.3
Resistance: Resistance1: 3.89    Resistance2: 4.54
Pivot: 3.68
Moving Average: MA(5): 3.76     MA(20): 3.62
MA(100): 3.22     MA(250): 2.63
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 79.8     %D(3): 83.8
RSI: RSI(14): 52.8
52-week: High: 4  Low: 1.77
Average Vol(K): 3-Month: 131 (K)  10-Days: 77 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ OCUP ] has closed below upper band by 45.3%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.83 - 3.85 3.85 - 3.87
Low: 3.65 - 3.67 3.67 - 3.69
Close: 3.76 - 3.79 3.79 - 3.82

Company Description

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Headline News

Tue, 21 Mar 2023
Myopia & Presbyopia Eye Drops Market Report: Analysis of Effective ... - Digital Journal

Mon, 20 Mar 2023
Glaucoma Pipeline Analysis Demonstrates Novel 70+ Companies at ... - Digital Journal

Mon, 20 Mar 2023
Ocuphire Pharma Inc : Profits of 97 cents per share ... - Kalkine Media

Mon, 20 Mar 2023
Soho House & Co Inc Says On March 17, Filed An Amendment To ... - Kalkine Media

Mon, 20 Mar 2023
Golub Capital Bdc Enters Into An Amended And Restated Senior ... - Kalkine Media

Mon, 20 Mar 2023
Cartica Acquisition Corp - Received Written Notice From Cartica ... - Kalkine Media

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 21 (M)
Shares Float 20 (M)
% Held by Insiders 4.3 (%)
% Held by Institutions 16.4 (%)
Shares Short 1,070 (K)
Shares Short P.Month 1,050 (K)

Stock Financials

EPS -5.63
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.19
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -73.3
Return on Equity (ttm) -137.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.71
Sales Per Share 0
EBITDA (p.s.) -1.07
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.66
PEG Ratio 0
Price to Book value 3.11
Price to Sales 0
Price to Cash Flow -3.84

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-11-05
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.